The coronavirus disease 2019 (COVID‐19) pandemic has resulted in the reorganization of health‐care settings affecting clinical care delivery to patients with Duchenne and Becker muscular dystrophy (DBMD) as well as other inherited muscular dystrophies. The magnitude of the impact of this public health emergency on the care of patients with DBMD is unclear as they are suspected of having an increased risk for severe manifestations of COVID‐19. In this article, the authors discuss their consensus recommendations pertaining to care of these patients during the pandemic. We address issues surrounding corticosteroid and exon‐skipping treatments, cardiac medications, hydroxychloroquine use, emergency/respiratory care, rehabilitation management, and the conduct of clinical trials. We highlight the importance of collaborative treatment decisions between the patient, family, and health‐care provider, considering any geographic or institution‐specific policies and precautions for COVID‐19. We advocate for continuing multidisciplinary care for these patients using telehealth.

中文翻译：

---

COVID-19 大流行期间杜氏肌营养不良症、贝克尔肌营养不良症和其他肌营养不良症患者的护理。

2019 年冠状病毒病 (COVID-19) 大流行导致医疗机构重组，影响了杜氏肌营养不良症和贝克尔肌营养不良症 (DBMD) 以及其他遗传性肌营养不良症患者的临床护理服务。此次突发公共卫生事件对 DBMD 患者护理的影响程度尚不清楚，因为人们怀疑他们出现 COVID-19 严重症状的风险增加。在本文中，作者讨论了他们在大流行期间护理这些患者的共识建议。我们解决围绕皮质类固醇和外显子跳跃治疗、心脏药物、羟氯喹使用、急诊/呼吸护理、康复管理和临床试验进行的问题。我们强调患者、家人和医疗保健提供者之间合作治疗决策的重要性，同时考虑到针对 COVID-19 的任何地理或机构特定政策和预防措施。我们主张利用远程医疗对这些患者进行持续的多学科护理。